Formulation and Characterization of “Ready to Use” 1B4M-DTPA-rituximab for Lu-177 Labeling

Gorgieva, Darinka and Smilkov, Katarina and Janevik-Ivanovska, Emilija (2014) Formulation and Characterization of “Ready to Use” 1B4M-DTPA-rituximab for Lu-177 Labeling. World Journal of Medical Sciences, 11 (4). pp. 535-540. ISSN 1817-3055

[img]
Preview
Text
Formulation and Characterization of “Ready to Use” 1B4M-DTPA-rituximab for Lu-177 Labeling.pdf

Download (244Kb) | Preview
Official URL: http://www.idosi.org/wjms/wjms11(4)14.htm

Abstract

Investigations for NHL treatment are oriented towards radiolabelled therapeutics. This research focuses on formulation and characterization of a new, ready to label immunoconjugate, 1B4M-DTPA-rituximab, which is suitable for labeling with Lu-177. The conjugation was performed using 20-fold molar excess of the bifunctional chelating agent, 1B4M-DTPA and subsequent lyophilization. The characterization of the (radio)immunoconjugate was performed using SE-HPLC, SDS-PAGE and MALDI-TOF-MS. The results show that the conjugation reaction yields immunoconjugates with average of 8.3 chelating groups per one rituximab molecule and the subsequent lyophilization did not affect the integrity, the structure, or radionuclide-binding properties. The radiolabelling with 555 GBq/mg Lu-177 resulted in over 95% radiochemical purity, which makes this agent a good candidate for further investigation of biological and pharmacological potency in NHL therapy.

Item Type: Article
Subjects: Medical and Health Sciences > Health biotechnology
Medical and Health Sciences > Health sciences
Divisions: Faculty of Medical Science
Depositing User: Emilija Janevik
Date Deposited: 26 Nov 2014 10:22
Last Modified: 26 Nov 2014 10:22
URI: http://eprints.ugd.edu.mk/id/eprint/11464

Actions (login required)

View Item View Item